Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ruzinurad Tablet Sizes in Healthy Subjects
NCT06168929Phase 1Completed
- Sponsor
- Hengrui
- Start
- Dec 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ruzinurad in hyperuricemia (2 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Started Dec 2023; status: completed.
02
Drugs
ruzinurad
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on NCT06168929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06168929.